Search clinical trials for: GD2-CART01 (iC9-GD2-CAR T-cells)

Total 959 results

Bambino Gesù Hospital and Research Institute

Recruiting

GD2-CAR T Cells for Pediatric Brain Tumours

High Grade Glioma | Medulloblastoma, Childhood | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma | Embryonal Tumor | Brain Tumor Adult | Brain Tumor, Pediatric

Italy
University College, London

Recruiting

CAR T Cells to Target GD2 for DMG (CARMIGO)

Diffuse Midline Glioma, H3 K27M-Mutant

United Kingdom
University College, London

Not yet recruiting

Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma (MAGNETO)

Neuroblastoma
Sinobioway Cell Therapy Co., Ltd.
Children's Hospital of Fudan University; Nanjing Children's Hospital

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children

Relapsed or Refractory Neuroblastoma

China
UNC Lineberger Comprehensive Cancer Center
United States Department of Defense; Bellicum Pharmaceuticals

Recruiting

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Small Cell Lung Carcinoma | Lung Cancer | Non Small Cell Lung Cancer

United States
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital

Recruiting

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Neuroblastoma

China
Baylor College of Medicine
Cancer Prevention Research Institute of Texas; The Methodist Hospital Research... and other collaborators

Active, not recruiting

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

Refractory Neuroblastoma | Uveal Melanoma | Relapsed Ewing Sarcoma | Relapsed Osteosarcoma | Relapsed Neuroblastoma | Relapsed Rhabdomyosarcoma | Phyllodes Breast Tumor

United States
Children's Mercy Hospital Kansas City
Center for Cell and Gene Therapy, Baylor College of Medicine

Completed

Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma (STALLONe)

Neuroblastoma

United States
Bambino Gesù Hospital and Research Institute

Recruiting

Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors

Sarcoma | Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Neuroblastoma Recurrent | GD2-positive Solid Tumors

Italy
Baylor College of Medicine
National Cancer Institute (NCI); The Methodist Hospital Research Institute; Center... and other collaborators

Active, not recruiting

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN (GRAIN)

Neuroblastoma

United States
Affiliated Hospital to Academy of Military Medical...

Unknown

Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies

Lymphoma | Leukemia

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33 (CART33)

Relapsed Adult Myeloid Leukemia | Chemotherapy Refractory Adult Myeloid Leukemia

China
Fuda Cancer Hospital, Guangzhou

Withdrawn

CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients

CAR-T Cell Immunotherapy | Glioma of Brain
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine; The Faris Foundation and other collaborators

Recruiting

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

High Grade Glioma | Diffuse Intrinsic Pontine Glioma | Embryonal Tumor | Ependymal Tumor

United States
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD56 Bi-specific CAR-T Cell Therapy

Malignant Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/PSMA Bi-specific CAR-T Cell Therapy

Solid Tumor

China
Shenzhen Geno-Immune Medical Institute

Unknown

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Solid Tumor

China
Chimeric Therapeutics

Recruiting

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme of Brain

United States
920th Hospital of Joint Logistics Support Force...

Recruiting

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia

Acute Myeloid Leukemia

China
Miltenyi Biomedicine GmbH
DLR German Aerospace Center

Terminated

MB-CART20.1 Melanoma

Melanoma (Skin)

Germany
Miltenyi Biomedicine GmbH

Active, not recruiting

MB-CART20.1 Lymphoma

Non-Hodgkin's Lymphoma | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

Germany
Chinese PLA General Hospital

Recruiting

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas (CART30)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

China
Baylor College of Medicine
National Cancer Institute (NCI); The Methodist Hospital Research Institute; Center...

Active, not recruiting

iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (VEGAS)

Osteosarcoma | Neuroblastoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma

United States
Peking Union Medical College Hospital
Cellular Biomedicine Group Ltd.

Completed

A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

B-cell Non-Hodgkin Lymphoma

China
Daniel Landi

Terminated

EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma (ExCeL)

Glioblastoma | Gliosarcoma

United States
Zhujiang Hospital

Completed

Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma (4SCAR-GD2)

Effects of Immunotherapy | Neuroblastoma

China
University of Pennsylvania
University of California, San Francisco

Terminated

Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

Patients With Residual or Reccurent EGFRvIII+ Glioma

United States
University of Pennsylvania

Completed

CART-19 for Multiple Myeloma

Multiple Myeloma

United States
Beijing GoBroad Hospital

Not yet recruiting

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-Cell Acute Lymphocytic Leukemia
University of Colorado, Denver

Recruiting

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Acute Lymphoblastic Leukemia | Acute Lymphoid Leukemia

United States
Stephan Grupp MD PhD
University of Pennsylvania

Recruiting

Co-administration of CART22-65s and huCART19 for B-ALL

B-cell Acute Lymphoblastic Leukemia | B Lineage Lymphoblastic Lymphoma

United States
Dipenkumar Modi
Genmab

Recruiting

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Relapsed Cancer | Refractory Cancer | Large Cell Lymphoma, Diffuse

United States
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
UNC Lineberger Comprehensive Cancer Center
United States Department of Defense; Bellicum Pharmaceuticals; University Cancer...

Recruiting

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Osteosarcoma | Neuroblastoma

United States
The First Affiliated Hospital of Soochow University

Recruiting

Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine; Alex's Lemonade...

Withdrawn

3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA (GINAKIT)

Neuroblastoma

United States
Cancer Institute and Hospital, Chinese Academy...
UTC Therapeutics Inc.

Not yet recruiting

MSLN-targeted CAR-T Cells in Solid Tumors.

Mesothelin-positive Advanced Malignant Solid Tumors
BioSyngen Pte Ltd

Completed

A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

EBV-positive Nasopharyngeal Carcinoma

China
Seattle Children's Hospital

Active, not recruiting

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

CD 19+ Acute Leukemia

United States
Wuhan Sian Medical Technology Co., Ltd
Wuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaborators

Unknown

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

B Cell Lymphoma | Acute Lymphoblastic Leukemia

China
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell

China
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological Malignancies

Infectious Diseases | Hematological Malignancies

China
He Huang
Gracell Biotechnology Ltd.

Not yet recruiting

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Zhejiang University

Recruiting

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia

China
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Completed

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China
Peking University People's Hospital

Not yet recruiting

CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

T-cell Non-Hodgkin's Lymphoma

Search clinical trials for: GD2-CART01 (iC9-GD2-CAR T-cells)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations